Here’s an honest admission: Even covering women’s health every day, I didn’t fully appreciate how many distinct conditions fall under the umbrella of “incontinence” until 3 companies raised a combined $121 million in the space of a single week. Incontinence tends to get treated as one vague, uncomfortable category that nobody wants to discuss in detail. But this wave of funding made something clear - it’s actually several distinct medical conditions with different causes, different mechanisms, and now very different treatment approaches attracting serious capital.
UroMems raised $60 million. BlueWind Medical raised $47.8 million. NinaMED launched with $13.75 million. Each targets a different type of incontinence. Each is building a different kind of device. And taken together, they represent one of the largest concentrations of capital we’ve seen flow into pelvic health in such a short window.
3 Conditions, 3 Approaches
To understand what these companies are building and why, it helps to understand that “incontinence” is not one thing.
Stress urinary incontinence (SUI) is involuntary leakage triggered by physical pressure on the bladder - coughing, sneezing, laughing, lifting, running. It’s caused by weakening of the pelvic floor muscles and the urethral sphincter, and it disproportionately affects women after childbirth, during menopause, and as they age. An estimated 40 million Americans and 90 million Europeans live with SUI. UroMems is developing UroActive, a smart automated artificial urinary sphincter. The device is implanted around the urethral duct and adjusts automatically based on the patient’s activity - no manual operation required. That’s a significant advance over existing artificial sphincters, which require patients to manually pump a valve to open and close the urethra, and which carry high complication rates. Protected by over 200 patents, UroActive is currently in a pivotal trial across 21 centers in the U.S. and France.
Urgency urinary incontinence (UUI) is a sudden, intense need to urinate followed by involuntary leakage - the bladder contracts when it shouldn’t. It’s driven by overactive nerve signaling to the bladder muscle, and it’s particularly common during and after menopause as hormonal changes affect bladder function. BlueWind Medical is commercializing Revi, a tiny implant placed near the ankle in a single outpatient procedure under local anesthesia. It delivers targeted stimulation to the posterior tibial nerve via a lightweight external wearable that patients activate once daily at home. Unlike other neuromodulation implants, Revi has no internal batteries or leads - eliminating the risk of lead fracture, migration, or battery depletion. 3-year results from its pivotal OASIS study confirmed sustained efficacy and 95% patient satisfaction.
Overactive bladder (OAB) is related to but distinct from UUI. It’s characterized by a sudden, frequent urge to urinate that’s difficult to control, and may or may not involve leakage. OAB affects an estimated 550 million people worldwide and is one of the most significant underserved conditions in urology. NinaMED is developing a completely non-invasive wearable that targets the saphenous nerve - a shallow sensory nerve in the upper calf that was discovered and patented as a therapeutic target at the University of Toronto. The device enables at-home treatment sessions with no implant, no drugs, and no clinic visits required.
Why Current Treatments Aren’t Working
The scale of the opportunity becomes clearer when you look at what’s currently available - and why so many women abandon treatment.
The first-line treatment for most incontinence conditions is medication, typically anticholinergic drugs. But these come with systemic side effects - dry mouth, constipation, blurred vision, cognitive impairment - and discontinuation rates are high, with some studies reporting up to 80% of patients stopping their medication. For OAB specifically, beta-3 agonists offer an alternative but are expensive and not effective for everyone. Botulinum toxin injections work but require repeated in-clinic procedures. And the surgical options - sacral neuromodulation implants, sling procedures, artificial sphincters - are invasive, carry complication risks, and are typically reserved for severe cases.
What all 3 of these companies are building sits in the gap between pills that don’t work well enough and surgery that’s too invasive for most patients. NinaMED is entirely non-invasive. BlueWind’s implant is minimally invasive (a single outpatient procedure under local anesthesia) with no batteries to replace. UroMems’ implant is more involved but eliminates the manual operation that makes existing sphincters impractical for many patients. The common thread is making effective treatment accessible to the much larger population of women who need more than medication but don’t want or qualify for major surgery.
The Condition Nobody Talks About
The prevalence numbers for urinary incontinence are enormous. Combined, the conditions these 3 companies are targeting affect hundreds of millions of people globally, the majority of them women. And yet incontinence remains one of the most underreported conditions in healthcare. Many women don’t bring it up with their doctors. Many clinicians don’t ask. The result is a massive gap between how many people are affected and how many are actually being treated.
Part of this is stigma - incontinence is embarrassing in a way that other chronic conditions simply aren’t. But part of it is normalization. Women are routinely told that leaking after childbirth is normal, that urgency during menopause is just something you live with, that this is what aging looks like. And while these conditions are common, they are not inevitable - and they are certainly not untreatable. The gap between prevalence and treatment is not a sign that patients don’t want help. It’s a sign that the available options haven’t been good enough to overcome the barrier of bringing it up in the first place.
What $121 Million Tells Us
When $121 million flows into a single clinical category in the space of a week, it’s worth asking what investors are seeing. A few things stand out.
First, these are all device plays - serious medtech with lengthy R&D timelines, regulatory pathways, and clinical trials. This is not the kind of capital that chases quick returns. UroMems is in a pivotal trial across 21 centers. BlueWind has 3-year efficacy data. NinaMED has multiple feasibility studies behind it. Investors are backing these companies because the clinical evidence is maturing, not because the market is trendy.
Second, the market dynamics are straightforward. Hundreds of millions of potential patients, a majority of them women. Current treatments with high discontinuation rates. A massive gap between prevalence and treatment. And a clinical pathway - neuromodulation - that’s increasingly proven but still underdeployed. The commercial case doesn’t require optimistic projections. It requires better products.
Third, and perhaps most importantly, what’s happening in incontinence reflects a broader pattern in pelvic health: Conditions that were historically normalized, underfunded, and underdiscussed are attracting serious innovation precisely because the gap between need and treatment is so wide. Pelvic health is one of the most underserved categories in all of medicine. The capital that flowed into it this week is a sign that investors are beginning to see what patients have known for a long time - that these conditions deserve better treatment, and that the companies building it will find an enormous market waiting.
